Table 1.

Clinical trials investigated the anti-COVID-19 effects of ivermectin

	Number of patients	Country of study	Ivermectin dose	Description/outcome	References
Positive responded studies	280	United States	200 mg/kg/day	1) Reduced mortality in both general and severe lung disease patients compared to the control 2) No significant difference in length of hospitalization relative to the control	Rajter et al. (2021)
	69	Iran	0.2 mg/kg/day	Significantly reduced mean dyspnea, persistent cough, hospitalization, and incidence of lymphopenia	Shahbaznejad et al. (2021a)
	72	Bangladesh	12 mg	The safety and effectiveness of Ivermectin were confirmed as well as the effect of Ivermectin on the virus clearance rate and improvement of clinical symptoms	Ahmed et al. (2021)
	66	Turkey	200 µg/kg/day	Improved clinical recovery, improve prognostic test indicators, and reduce mortality	Okumuş et al. (2021)
Negative responded studies	125	India	12 and 24 mg/day	Increased negative RT-PCR tests or decreased viral loads in patients receiving Covid19, but no statistically significant difference compared with the placebo group	Mohan et al. (2021)
	490	Malaysia	0.4 mg/kg/day	No significant difference compared to the control, so treatment with Ivermectin in the early stages of COVID-19 could not prevent the disease from progressing to more serious stages	Lim et al. (2022b)
	501	Argentina	12 and 18 mg/day	No significant difference compared to the control	Vallejos et al. (2021)
	476	Colombia	300 g/kg/day	No significant improved symptom remission of COVID-19	López-Medina et al. (2021)
	100	Lebanon	9 mg, 12 mg, and 150 µg/kg	1) Significantly elevated Ct values compared with the control group 2) Fewer symptoms, lower viral loads, and fewer hospitalizations compared with the control group	Samaha et al. (2021)